Why this Seattle Genetics drug trial is worth watching
Cancer drug company Seattle Genetics (Nasdaq: SGEN) just released positive results of a five-year follow-up to an earlier clinical trial, but the real trial to watch is still going on.
That drug trial, called Echelon-1, is trying out Seattle Genetics’ Adcetris drug in new way, using it as a first line of treatment for patients with advanced classical Hodgkin lymphoma instead of as a last resort for the cancer. If successful with previously untreated Hodgkin lymphoma, the trial could lead to expanded…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Rachel Nielsen Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Health | Health Management | Lymphoma | Pharmaceuticals